Literature DB >> 7509379

Paclitaxel: what schedule? What dose?

S G Arbuck.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7509379     DOI： 10.1200/JCO.1994.12.2.233

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Breast cancer therapies in development. A review of their pharmacology and clinical potential.

Authors:  D de Valeriola; A Awada; J A Roy; A Di Leo; L Biganzoli; M Piccart
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy.

Authors:  A I Einzig; P H Wiernik; S Wadler; J Kaplan; L T Benson; L Tentoramano; V Tan
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

Review 3.  Clinical pharmacokinetics of paclitaxel.

Authors:  D S Sonnichsen; M V Relling
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

4.  Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.

Authors:  Y Kano; M Akutsu; S Tsunoda; J Ando; J Matsui; K Suzuki; T Ikeda; Y Inoue; K Adachi
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.